Tag:
Kala Pharmaceuticals
Latest Headlines
Latest Headlines
Langer's Kala touts positive results for topical wet AMD treatment
Kala Pharmaceuticals is developing a novel way to get drugs into the eye, and the company notched some positive results in preclinical studies, finding that its platform led to higher drug concentration for a retinal treatment.
Entrega, other startups make strides in needle-free delivery
Boston startup Entrega is developing a novel drug-delivery capsule that could give the company a foothold in a $200 billion arena just begging for more needle-free options, paving the way for the more elegant delivery of treatments for diseases such as Parkinson's, cancer and arthritis.
Langer biotech Kala earmarks $11.5M round for next-gen ophthalmology drugs
The new CEO at Kala Pharmaceuticals has landed an $11.5 million A round and mapped out plans to devote much of the cash to lead programs on wet, age-related macular degeneration and ocular inflammation.
Langer's Kala scores Cystic Fibrosis Foundation grant
Kala Pharmaceuticals received a grant from the Cystic Fibrosis Foundation to demonstrate that the company's mucosal-barrier-penetrating nanoparticle can do the same across bacterial biofilms, a symptom of cystic fibrosis.
Targacept taps Stephen A. Hill to serve as president and CEO
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Ex-Sanofi exec takes helm at Bob Langer startup
Mucosal delivery company Kala Pharmaceuticals has welcomed Guillaume Pfefer, ex-general manager of Sanofi Pasteur Mexico, as its new president and CEO. Kala's co-founder, Justin Hanes, has published data on the company's mucosal-penetrating products (MPPs) in Science Translational Medicine.
New Kala CEO plans to raise funds for particle tech programs
The startup biotech Kala Pharmaceuticals has taken another step forward in its journey to the clinic. The Waltham, MA-based developer of mucus-penetrating particle treatments--one of Robert Langer's portfolio of startups--has wooed Gillaume Pfeffer into the top spot.
Langer upstart rakes in fresh venture cash for mucus-targeting drugs
An upstart biotech company with intriguing new formulation technologies and a roster of influential backers has rounded up $6.2 million in additional seed capital.
Kala Pharmaceuticals, co-launched by MIT's Langer, snags $6.2M
Kudos to Kala Pharmaceuticals. The early-stage developer of treatments designed to reach mucosal organs just brought in an additional $6.2 million in equity financing to help carry various preclinical programs to human clinical trials.
